Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3198
Durham, NC 27710
Appointment Telephone
877-727-2385
Office Telephone
919-681-6932
Fax Telephone
919-684-5163
Clinical Interests
Treatment and management of patients with soft-tissue and bone sarcomas
Research Interests
Novel therapies for soft tissue and bone sarcomas
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
Representative Publications
Riedel, RF. Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer. 2012;118:1474-1485.
(2012)
Abstract
Palta, M; Riedel, RF; Vredenburgh, JJ; Cummings, TJ; Green, S; Chang, Z; Kirkpatrick, JP. Primary meningeal rhabdomyosarcoma. Sarcoma. 2011;2011:312802.
(2011)
Abstract
Smith, JL; Riedel, RF. Emerging therapeutic targets for soft tissue sarcoma. Current Oncology Reports. 2011;13:350-358.
(2011)
Abstract
Demetri, GD; Antonia, S; Benjamin, RS; Bui, MM; Casper, ES; Conrad, EU; DeLaney, TF; Ganjoo, KN; Heslin, MJ; Hutchinson, RJ; Kane, JM; Letson, GD; McGarry, SV; O'Donnell, RJ; Paz, IB; Pfeifer, JD; Pollock, RE; Randall, RL; Riedel, RF; Schupak, KD; Schwartz, HS; Thornton, K; von Mehren, M; Wayne, J; National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. Soft tissue sarcoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8:630-674.
(2010)
Abstract
Demetri, GD; von Mehren, M; Antonescu, CR; DeMatteo, RP; Ganjoo, KN; Maki, RG; Pisters, PW; Raut, CP; Riedel, RF; Schuetze, S; Sundar, HM; Trent, JC; Wayne, JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8 Suppl 2:S1-41.
(2010)
Abstract
Mito, JK; Riedel, RF; Dodd, L; Lahat, G; Lazar, AJ; Dodd, RD; Stangenberg, L; Eward, WC; Hornicek, FJ; Yoon, SS; Brigman, BE; Jacks, T; Lev, D; Mukherjee, S; Kirsch, DG. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One. 2009;4:e8075.
(2009)
Abstract
Riedel, RF; Larrier, N; Dodd, L; Kirsch, D; Martinez, S; Brigman, BE. The clinical management of chondrosarcoma. Current Treatment Options in Oncology. 2009;10:94-106.
(2009)
Abstract
Riedel, RF; Porrello, A; Pontzer, E; Chenette, EJ; Hsu, DS; Balakumaran, B; Potti, A; Nevins, J; Febbo, PG. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Molecular Cancer Therapeutics. 2008;7:3141-3149.
(2008)
Abstract
Hsu, DS; Balakumaran, BS; Acharya, CR; Vlahovic, V; Walters, KS; Garman, K; Anders, C; Riedel, RF; Lancaster, J; Harpole, D; Dressman, HK; Nevins, JR; Febbo, PG; Potti, A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. Journal of Clinical Oncology. 2007;25:4350-4357.
(2007)
Abstract
Riedel, RF; Andrews, C; Garst, J; Dunphy, F; Herndon, JE; Blackwell, S; Barbour, S; Crawford, J. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2007;2:520-525.
(2007)
Abstract
Riedel, RF; Burfeind, WR. Thymoma: benign appearance, malignant potential. The Oncologist. 2006;11:887-894.
(2006)
Abstract
Riedel, RF; Crawford, J; Dunphy, F; Herndon, JE; Garst, J; Kelley, MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer. 2006;54:431-432.
(2006)
Abstract
Riedel, RF; Wang, X; McCormack, M; Toloza, E; Montana, GS; Schreiber, G; Kelley, MJ. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. Journal of Thoracic Oncology. 2006;1:692-696.
(2006)
Abstract
Riedel, RF; Febbo, PG. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology. 2005;1:461-466.
(2005)
Abstract
Riedel, RF; Crawford, J. Small-cell lung cancer: a review of clinical trials. Seminars in Thoracic and Cardiovascular Surgery. 2003;15:448-456.
(2003)
Abstract
Luetteke, NC; Qiu, TH; Fenton, SE; Troyer, KL; Riedel, RF; Chang, A; Lee, DC. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (Cambridge). 1999;126:2739-2750.
(1999)
Abstract
Salomoni, P; Wasik, MA; Riedel, RF; Reiss, K; Choi, JK; Skorski, T; Calabretta, B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. Journal of Experimental Medicine. 1998;187:1995-2007.
(1998)
Abstract
